| Bioactivity | Sembragiline (EVT 302; RG1577) is a potent, selective and reversible monoamine oxidase B (MAO-B) inhibitor. Sembragiline reduces the metabolism of dopamine and other amine neurotransmitters by inhibiting the activity of the MAO-B enzyme, thereby potentially increasing the concentration of these neurotransmitters in the brain. Inhibition of the MAO-B enzyme also reduces the formation of toxic reactive oxygen species (ROS) that play a role in the pathological process of AD. Sembragiline has good oral activity and blood-brain barrier permeability. Sembragiline can be used in studies of AD, especially in patients with AD who show increased MAO-B activity[1]. |
| CAS | 676479-06-4 |
| Formula | C19H19FN2O3 |
| Molar Mass | 342.36 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Sturm S, et al. Positron emission tomography measurement of brain MAO-B inhibition in patients with Alzheimer’s disease and elderly controls after oral administration of sembragiline[J]. European journal of nuclear medicine and molecular imaging, 2017, 44: 382-391. |
Sembragiline
CAS: 676479-06-4 F: C19H19FN2O3 W: 342.36
Sembragiline (EVT 302; RG1577) is a potent, selective and reversible monoamine oxidase B (MAO-B) inhibitor. Sembragiline
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.